PEOPLE - Cordis makes appointment
This article was originally published in Clinica
In a move to stay at the forefront of innovation and drug-device combination product development, the J&J interventional vascular technology company Cordis (Miami Lakes, Florida) has appointed Campbell Rogers to the newly-created position of chief technology officer - effective from early July. Dr Rogers was most recently associate professor of medicine at Harvard Medical School (Massachusetts) and director of the cardiac catheterisation laboratory, the Brigham and Women's Hospital (Boston). His diverse expertise includes cardiac device and pharmacologic trials, and cardiac catheterisation clinical research and care.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.